An observational study in Pemphigus Disease and Rituximab (RTx), sponsored by Ruijin Hospital. Completed at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Ruijin Hospital · Observational
Investigating the clinical efficacy of different doses of rituximab in patients with pemphigus
Pemphigus is a severe autoimmune skin disease traditionally treated with systemic corticosteroids and immunosuppressants. Recent studies have highlighted the superior efficacy of rituximab combined with systemic corticosteroids, establishing this combination as a first-line treatment for pemphigus patients.
Currently, the administration protocols for rituximab in pemphigus patients often refer to the dosage used for rheumatoid arthritis: two intravenous infusions of 500 mg or 1000 mg spaced two weeks apart, with an additional 500 mg infusion after 6 to 9 months if necessary. Recently, several studies have reported successful treatment of pemphigus using low-dose (single 500 mg dose) or ultra-low-dose (single 200 mg dose) rituximab.
As an optimal dosage regimen for pemphigus has yet to be established, we conducted a retrospective cohort study to evaluate the efficacy of different rituximab dosages and explore the optimal dosing strategy for the treatment of pemphigus.
76 studies on the registry are indexed under Pemphigus; 18 are open to participants now.
This study's enrollment of 275 is above the median of 60 across 21 observational studies indexed under Pemphigus.
Browse Pemphigus studies →Ruijin Hospital is the lead sponsor of 679 studies on the registry; 387 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients who had a clinical presentation of active pemphigus combined with immunological or pathological evidence, and received rituximab
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
one dose of 500mg RTX
two doses of 500mg RTX
two doses of 1000mg RTX
relapse
according to Pemphigus S2 Guideline，patient who has achieved disease control appears ≥3 new lesions/month that do not heal spontaneously within 1 week, or patient's established lesions extend
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
disease control
according to Pemphigus S2 Guideline, patients' new lesions cease to form and established lesions begin to heal
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
adverse evert
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
dose of glucocorticoids
According to the clinical glucocorticoid dosage record
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
immunoglobulin levels
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
Concomitant medication
According to the clinical medication record
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
serum anti-Dsg1 and Dsg3 autoantibody levels
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
peripheral CD19+ cell counts
Time frame: week 4, 8, 12, 24, 36, 48 after treatment
Ran from Jan 2019 to primary completion in Jan 2023, 48 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.